Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 644

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 644
---
 development expense. In 2022, the Company recognized rent expense totaling $219,093 of which $133,705 was fixed and $85,388 was variable. Of the total rent expense recognized in 2022, $55,237 was charged to general and administrative expense and $163,856 to research and development expense.

| F-119 |

<div align='center'>CEREVAST MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS</div>

The aggregate future lease payments for operating leases as of December 31, 2023 are as follows:

| Year Ending December 31,             
 2024                                 |     | Future Minimum Lease Payments | 141,651 |   |
|:-------------------------------------|:----|:------------------------------|--------:|:--|
| 2025                                 |     |                               | 160,935 |   |
| 2026                                 |     |                               |  13,458 |   |
| Total lease payments                 |     |                               | 316,044 |   |
| Less amount representing interest    |     |                               | (40,013 | ) |
| Total operating lease obligation     |     | $                             | 276,031 |   |
| Balance Sheet Classification:        |     |                               |         |   |
| Operating lease obligation - current |     | $                             | 112,655 |   |
| Operating lease obligation           |     |                               | 163,376 |   |
| Total operating lease obligation     |     | $                             | 276,031 |   |

Note 11 – Contribution and Exchange Agreement and Merger Agreement

On August 7, 2022, the Company and each of its shareholders entered into a Contribution and Exchange Agreement (the “C&E Agreement”) with Longevity, a related party (see Note 6). In connection with the signing of the C&E Agreement, Longevity entered into similar agreements with certain other development stage medical technology and life science companies (collectively, along with Cerevast, the “Target Companies”). Upon the consummation of the transactions contemplated by the C&E Agreement and the agreements with the other Target Companies (collectively the “Acquisition Transactions”), the Target Companies will be acquired by Longevity.

The consummation of the Acquisition Transactions is conditioned upon the satisfaction or waiver of certain closing conditions including the entering into and subsequent closing of an approved business combination agreement with a blank-check special purpose acquisition company.

The parties to the C&E Agreement have made